Brimo
Generic Name
Brimonidine Tartrate 0.2% Ophthalmic Solution
Manufacturer
Generic Manufacturer (e.g., Square Pharmaceuticals Ltd.)
Country
Bangladesh (example)
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| brimo 02 eye drop | ৳ 80.30 | N/A |
Description
Overview of the medicine
Brimonidine Tartrate 0.2% Ophthalmic Solution is an alpha-2 adrenergic agonist indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
Uses & Indications
Dosage
Adults
Instill one drop in the affected eye(s) two or three times daily, approximately 8 hours apart. Consult a physician for specific dosing instructions.
Elderly
No dosage adjustment is generally necessary for elderly patients.
Renal_impairment
Use with caution in patients with renal impairment. Dose adjustment may be necessary due to minimal systemic absorption, consult a physician.
How to Take
For ophthalmic use only. Tilt head back, pull down the lower eyelid to form a pouch, and instill one drop into the conjunctival sac. Do not touch the dropper tip to the eye or any other surface to avoid contamination.
Mechanism of Action
Brimonidine is a highly selective alpha-2 adrenergic agonist that reduces elevated intraocular pressure by decreasing aqueous humor production and increasing uveoscleral outflow.
Pharmacokinetics
Onset
Approximately 1 hour
Excretion
Excreted primarily via the kidneys as metabolites.
Half life
Approximately 3 hours (systemic)
Absorption
Brimonidine is rapidly absorbed into the anterior segment of the eye after topical ocular administration. Systemic absorption occurs but is generally low.
Metabolism
Primarily metabolized in the liver via aldehyde oxidase. It undergoes extensive hepatic metabolism.
Side Effects
Contraindications
- •Hypersensitivity to brimonidine tartrate or any component of the formulation.
- •Patients receiving monoamine oxidase (MAO) inhibitor therapy.
- •Neonates and infants (under 2 years of age) due to potential for serious systemic side effects.
Drug Interactions
MAO Inhibitors
Contraindicated due to potential for significant systemic reactions.
CNS Depressants
May enhance the CNS depressant effect of other drugs (e.g., alcohol, barbiturates, opiates, sedatives, anesthetics).
Tricyclic Antidepressants (TCAs)
TCAs may blunt the IOP-lowering effect of brimonidine.
Beta-blockers/Antihypertensives/Cardiac Glycosides
May potentiate the effects of these agents, leading to hypotension or bradycardia.
Storage
Store at controlled room temperature (20°C to 25°C), away from light and moisture. Do not freeze.
Overdose
Accidental oral ingestion of brimonidine has been reported to cause systemic side effects such as hypotension, bradycardia, hypothermia, cyanosis, and CNS depression (sedation, lethargy, coma). Treatment involves supportive and symptomatic care.
Pregnancy & Lactation
Pregnancy Category B. Animal studies show no evidence of harm to the fetus, but there are no adequate and well-controlled studies in pregnant women. Use during pregnancy only if clearly needed. Exercise caution when administered to a nursing mother due to potential for systemic absorption and excretion into breast milk.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Unopened: 2-3 years; After opening: 28 days.
Availability
Pharmacies, Hospitals
Approval Status
FDA Approved
Patent Status
Generic available, original patent expired
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in